Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Panitumumab

Data presented today at the 10th World Congress on Gastrointestinal Cancer shows that preemptive treatment reduced the incidence rate of grade two and higher skin toxicities by over 50 percent without additional side effect.

Eberhard-Karls-University publish series of p38 inhibitors

In this weeks JMC Eberhard-Karls-University publish a series of 2,4,5- and 1,2,4,5-substituted 2-thioimidazole p38 MAP kinase inhibitors